Clinical Trial Update: Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome

View source ↗

Summary

This clinical trial is evaluating whether sulphonylureas improve neurodevelopmental outcomes in individuals with KCNJ11-related iDEND syndrome and is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder
• Autism Spectrum Disorder
• Developmental Delay
• Epilepsy
• Intellectual Disability
• Kcnj11-related Neonatal Diabetes Mellitus
• Neurodevelopmental Disorders

Drugs mentioned

• Glyburide (glibenclamide) (glibenclamide)

Snippet

Sponsor: Royal Devon and Exeter NHS Foundation Trust | Conditions: Neurodevelopmental Disorders, Intellectual Disability | Status: RECRUITING